Clonal autoantibodies identify microbial antigen as trigger of autoreactive B cells in systemic sclerosis

This study demonstrates that systemic sclerosis-associated autoantibodies against human topoisomerase 1 can cross-react with structurally homologous topoisomerase 1 from fungi, providing functional evidence that microbial antigens may trigger and perpetuate B cell-mediated autoimmunity in this disease.

The Gist

The Big Picture: A Case of Mistaken Identity

Imagine your immune system is a highly trained security team for your body. Its job is to spot intruders (like bacteria or viruses) and stop them. However, in a disease called Systemic Sclerosis (SSc), this security team gets confused. It starts attacking your own body's internal organs (like your skin and lungs) instead of just the bad guys.

This specific paper investigates why the security team gets confused in the first place. The researchers found a strong clue: The confusion might start with a fungus.

The Cast of Characters

• The Target (Topoisomerase 1 or TOP1): Think of this as a specific lock on a door inside your cells. In healthy people, the security team ignores this lock. In SSc patients, the security team builds a "wanted poster" (an antibody) for this lock and tries to break it down.
• The Intruder (Microbes): Bacteria, viruses, and fungi that live on or inside us.
• The Mimic: A specific type of fungus, Saccharomyces cerevisiae (the same yeast used to make bread and beer), which has a lock that looks almost identical to the one inside your cells.

The Story Unfolds

1. The "Look-Alike" Discovery

The researchers used a super-smart computer program (like a high-tech facial recognition system) to compare the "locks" (proteins) inside human cells with locks found in microbes.

• The Finding: They discovered that the lock inside human cells looks remarkably similar to the lock found on a common yeast (S. cerevisiae). Even though they aren't made of the exact same materials (different amino acid sequences), their 3D shapes are nearly identical.
• The Analogy: Imagine you have a very specific key that opens your front door. Then, you find a key on the street that looks 90% identical to yours. If your security guard sees that street key, they might think, "Hey, that's the key to the house! Let's attack it!"

2. The Cross-Contamination

The researchers tested blood samples from SSc patients.

• The Result: Many patients who had antibodies (the "wanted posters") against their own human lock also had antibodies against the yeast lock.
• The Twist: This didn't happen in healthy people or in patients with a different type of autoimmune disease. It was specific to the SSc patients.
• The Analogy: It's as if the security guard saw the yeast key, got angry at it, and then decided to attack your actual house door because the two keys looked so similar. This is called molecular mimicry.

3. The "Wake-Up Call"

To prove this wasn't just a coincidence, the researchers created a simulation. They took B-cells (the soldiers that make the wanted posters) from a patient and showed them the yeast lock.

• The Result: The moment the B-cells saw the yeast lock, they woke up, got excited, and started attacking.
• The Analogy: The yeast didn't just look like the enemy; it actually triggered the alarm. The yeast acted as a spark that lit the fire of autoimmunity.

4. The Severity Connection

The most exciting part of the study is the link to how sick the patients were.

• The Finding: Patients with the most severe disease, especially those with serious lung scarring (Interstitial Lung Disease), were the ones most likely to have antibodies that recognized the yeast.
• The Analogy: Imagine two houses on fire. In the house with the small fire, the security guard is only slightly confused. In the house with the massive inferno, the security guard is completely obsessed with the "look-alike" key. The more the guard focuses on the yeast, the worse the damage to the house (the lungs).

Why Does This Matter?

1. It explains the "Spark": For a long time, doctors didn't know what started the fire in Systemic Sclerosis. This paper suggests that exposure to common fungi (like yeast in the gut or lungs) might be the spark that tricks the immune system into attacking the body.

2. It offers a new tool for doctors: Currently, doctors can tell if a patient has the disease, but it's hard to predict who will get very sick. This study suggests that testing for antibodies against the yeast (not just the human protein) could act as a "severity meter." If a patient has high levels of anti-yeast antibodies, they might need more aggressive treatment to protect their lungs.

3. New Treatment Ideas: If the yeast is the trigger, maybe we can treat the disease by:

• Changing the diet to reduce yeast exposure.
• Using antifungal medications.
• Designing drugs that specifically stop the immune system from reacting to the yeast, without hurting the rest of the body.

The Bottom Line

This paper tells us that in Systemic Sclerosis, the immune system might be getting tricked by a common yeast. The yeast wears a "disguise" that looks like a part of our own body. When the immune system attacks the yeast, it accidentally starts attacking our lungs and skin. The worse the disguise (the more the immune system reacts to the yeast), the sicker the patient gets.

It's a classic case of "The enemy of my enemy is my friend," except in this case, the immune system thinks the friend is the enemy, and the enemy is actually just a harmless piece of bread yeast!

Technical Summary

1. Problem Statement

Systemic Sclerosis (SSc) is a chronic, heterogeneous autoimmune disease characterized by vasculopathy and fibrosis. A hallmark of the disease, particularly in the diffuse cutaneous subset, is the presence of anti-topoisomerase 1 autoantibodies (ATAs) targeting the human nuclear protein Topoisomerase 1 (TOP1). While B-cell depletion therapies (e.g., rituximab, CAR-T cells) have shown efficacy, the specific triggers that initiate and sustain the break in B-cell tolerance against human TOP1 remain undefined. The authors hypothesize that molecular mimicry—where microbial antigens structurally resemble human TOP1—may trigger autoreactive B cells, leading to cross-reactivity and disease perpetuation.

2. Methodology

The study employed a multi-disciplinary approach combining computational biology, immunology, and clinical cohort analysis:

• Computational Structural Homology Search:

  • Used Foldseek to search for microbial proteins with tertiary structures similar to human TOP1 (PDB ID: 1EJ9).
  • Applied taxonomic filters for fungi, bacteria, and viruses.
  • Selected Saccharomyces cerevisiae (baker's yeast) TOP1 as a prototype due to high structural homology scores despite low sequence identity.

• Recombinant Protein Production:

  • Purified recombinant human TOP1 and S. cerevisiae TOP1 for experimental use.

• Clinical Cohorts:

  • Cohort 1 (n=58): Plasma from ATA+ SSc, ACA+ SSc, and Healthy Donors (HDs) to screen for cross-reactivity.
  • Cohort 2 (n=59): Serum from ATA+ SSc patients stratified into "severe" (n=18) and "mild" (n=21) disease phenotypes based on clinical expertise, plus controls.
  • Cohort 3 (n=243): A large, unselected cohort of ATA+ SSc patients (n=163) and controls to validate associations with Interstitial Lung Disease (ILD).

• In Vitro Immunological Assays:

  • ELISA: Measured IgG reactivity against human and S. cerevisiae TOP1 in patient sera.
  • Monoclonal Antibodies (mAbs): Generated seven patient-derived ATA mAbs from a single ATA+ patient. Tested their binding to human and yeast TOP1.
  • B Cell Activation Assay: Created Ramos B cell lines expressing specific patient-derived B-cell receptors (BCRs). Stimulated these cells with human and yeast TOP1 and measured activation via phosphorylation of Syk (pSyk) using flow cytometry.

• Statistical Analysis:

  • Used non-parametric tests (Kruskal-Wallis, Mann-Whitney U) for group comparisons and Spearman's rank correlation for associations. Adjusted odds ratios were calculated for clinical associations.

3. Key Contributions

• Identification of Microbial Mimicry: Provided the first functional evidence that human TOP1-reactive B cells can be triggered by microbial TOP1, specifically from fungi like S. cerevisiae.
• Mechanistic Proof of B Cell Activation: Demonstrated that microbial TOP1 is not merely recognized by antibodies but can directly activate autoreactive B cells expressing patient-derived BCRs, bypassing the need for initial T-cell tolerance breaking against the human antigen.
• Clinical Stratification Biomarker: Identified that the recognition of microbial TOP1 is significantly associated with severe disease phenotypes, specifically clinically relevant Interstitial Lung Disease (ILD), offering a potential biomarker for risk stratification beyond standard anti-human TOP1 testing.

4. Key Results

• Structural Conservation: Foldseek analysis revealed strong structural homology between human TOP1 and TOP1 from various microbes, particularly fungi (S. cerevisiae), despite low sequence identity (~41%).
• Cross-Reactivity in Sera:
  • In Cohort 1, 45% of ATA+ SSc patients recognized S. cerevisiae TOP1, whereas ACA+ patients and HDs did not.
  • In Cohort 2, 62% of ATA+ patients showed reactivity.
  • In Cohort 3, 77% of ATA+ patients were positive for anti-yeast TOP1 IgG.
• Monoclonal Antibody Cross-Reactivity:
  • Of seven patient-derived ATA mAbs, four (including 9D11) bound to S. cerevisiae TOP1 in a concentration-dependent manner.
  • The mAb 9D11 showed strong binding to yeast TOP1 at low concentrations.
• Functional B Cell Activation:
  • Ramos B cells expressing the 9D11 BCR were activated by S. cerevisiae TOP1 (evidenced by pSyk phosphorylation), confirming that microbial antigen can trigger the autoreactive B cell clone.
  • Control B cells (anti-citrullinated protein) were not activated by TOP1.
• Clinical Correlations:
  • Disease Severity: Patients with "severe" SSc had significantly higher levels of anti-S. cerevisiae TOP1 IgG compared to "mild" patients (83% vs. 43% seropositivity).
  • Interstitial Lung Disease (ILD): Recognition of microbial TOP1 was strongly associated with clinically relevant ILD. In Cohort 3, 90% of patients with ILD were anti-yeast TOP1 positive vs. 72% without ILD (Adjusted OR: 3.4, p=0.034).
  • Specificity: While anti-human TOP1 levels correlated with disease severity, the specific recognition of the microbial antigen provided additional discriminatory power for identifying patients with severe lung involvement.

5. Significance and Implications

• Pathogenesis: The study supports a model where environmental exposure to fungal antigens (e.g., in the lungs or gut) initiates an immune response. Through molecular mimicry, these responses cross-react with human TOP1, breaking B-cell tolerance. This process may be sustained by continuous exposure to commensal fungi, driving disease progression.
• Therapeutic Targets: The findings suggest that targeting the specific B-cell clones cross-reactive with microbial antigens, or modulating the mycobiome, could be novel therapeutic strategies.
• Clinical Utility: Measuring anti-S. cerevisiae TOP1 IgG could serve as a complementary biomarker to standard anti-human TOP1 testing. It may help stratify ATA+ patients into high-risk groups for severe fibrosis and ILD, allowing for earlier and more aggressive intervention.
• Broader Context: This work highlights the under-explored role of the mycobiome (fungal microbiome) in human autoimmunity, extending the concept of molecular mimicry beyond bacteria (e.g., Ro60 in Lupus) to fungi.

In conclusion, the paper establishes a direct functional link between microbial fungal antigens and the activation of autoreactive B cells in Systemic Sclerosis, providing a mechanistic explanation for disease heterogeneity and a potential new avenue for patient stratification.